Structure of Idebenone
CAS No.: 58186-27-9
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Idebenone, a synthetic analog of coenzyme Q10 (CoQ10), can protect mitochondrial membranes against lipid peroxidation and also used as a neuroprotective agent.
Synonyms: CV-2619; Mnesis; Catena, Raxone, Sovrima
4.5
*For Research Use Only !
Change View
| Size | Price | VIP Price |
DE Stock US Stock |
Asia Stock Global Stock |
In Stock |
| {[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock Inquiry - | Login - + |
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
| CAS No. : | 58186-27-9 |
| Formula : | C19H30O5 |
| M.W : | 338.44 |
| SMILES Code : | O=C1C(CCCCCCCCCCO)=C(C)C(C(OC)=C1OC)=O |
| Synonyms : |
CV-2619; Mnesis; Catena, Raxone, Sovrima
|
| MDL No. : | MFCD00274552 |
| InChI Key : | JGPMMRGNQUBGND-UHFFFAOYSA-N |
| Pubchem ID : | 3686 |
| GHS Pictogram: |
|
| Signal Word: | Warning |
| Hazard Statements: | H302-H315-H319-H332-H335 |
| Precautionary Statements: | P261-P280-P305+P351+P338 |
In Vitro:
|
Cell Line
|
Concentration | Treated Time | Description | References |
| Neonatal rat cardiomyocytes (NRCMs) | 5 μM | 24 h | To evaluate the protective effect of idebenone on DOX-induced cardiomyocyte toxicity, results showed that idebenone significantly improved the viability of DOX-treated cardiomyocytes. | Acta Pharm Sin B. 2024 Jun;14(6):2581-2597. |
In Vivo:
|
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
| C57BL/6J male mice | DOX-induced cardiotoxicity model | Oral gavage | 200 mg/kg | Once daily for 7 days | To evaluate the protective effect of idebenone on DOX-induced cardiotoxicity, results showed that idebenone significantly improved DOX-induced cardiac dysfunction and survival rate. | Acta Pharm Sin B. 2024 Jun;14(6):2581-2597. |
| Drosophila | Transgenic Drosophila expressing uN2CpolyG | Oral | 7, 15, 50 μM | Three times per week for 20 days | To evaluate the effect of idebenone on motor performance, lifespan, and mitochondrial function in transgenic flies, results showed that 15μM idebenone significantly improved motor performance, extended lifespan, and restored ATP synthesis levels. | Proc Natl Acad Sci U S A. 2022 Oct 11;119(41):e2208649119 |
| C57BL/6J mice | CCl4-induced liver fibrosis model | Intragastric administration | 50, 100 or 200 mg/kg | Daily administration for 4 weeks | Evaluate the therapeutic effect of IDE on liver fibrosis, results showed IDE significantly reduced liver inflammation and collagen accumulation | Cell Death Dis. 2024 Aug 20;15(8):602 |
Clinical Trial:
| NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
| NCT03014856 | - | Completed | - | - | |
| NCT00224640 | Friedreich Ataxia | Phase 1 Phase 2 | Completed | - | France ... More >> Necker Hospital Paris, France, 75015 Less << |
| NCT03014908 | - | Completed | - | Belgium ... More >> Hasselt University Hasselt, Limburg, Belgium, 3500 Less << | |
| NCT01421381 | - | Completed | - | Canada, Quebec ... More >> Hôpital Notre-Dame (CHUM) Montreal,, Quebec, Canada, H2L 4M1 Germany Friedrich Baur Institut Neurologische Klinik und Poliklinik München, Germany, D-80336 United Kingdom Biomedical Research Centre, The Medical School Newcastle upon Tyne, United Kingdom, NE2 4HH Less << | |
| NCT02774005 | Leber's Hereditary Optic Neuro... More >>pathy (LHON) Less << | PHASE4 | COMPLETED | 2021-03-29 | Retinal Consultants of Arizona... More >>, Phoenix, Arizona, United States|Palo Alto Medical Foundation, Palo Alto, California, 94040-2833, United States|Stanford Byers Eye Institute, Stanford, California, 94303, United States|University of Colorado Health Eye Center, Aurora, Colorado, United States|Emory University Hospital, Atlanta, Georgia, 30322, United States|Bethesda Neurology, LLC, Bethesda, Maryland, United States|Washington University, Saint Louis, Missouri, 63110, United States|New York Eye and Ear Infirmary, New York, New York, 10003, United States|University of Virginia, Charlottesville, Virginia, 22903, United States|AKH - Medizinische Universitaet Wien, Wien, Austria|CHU Saint-Pierre, Brussels, Belgium|Cliniques Universitaire Saint-Luc, Brussels, Belgium|UZ Leuven - Campus Sint-Rafa?l, Leuven, Belgium|C. H. U. Sart Tilman, Liège, Belgium|UMHAT "Alexandrovska" EAD, Sofia, Bulgaria|Friedrich-Baur-Institut, Muenchen, Germany|Università di Bologna-Clinica Neurologica-Dipartimento di Scienze Neurologiche, Bologna, Italy|SPZOZ Spital Uniwersytecki w Krakowie, Oddzial Kliniczny Okulistyki i Onkologii Okulistycznej, Krakow, 31-501, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego, Poznań, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 2 PUM w Szczecinie, Szczecin, Poland|Samodzielny Publiczny Kliniczny Szpital Okulistyczny, Warszawa, Poland|Uniwersytecki Szpital Kliniczny, Wroc?aw, Poland|Centro Hospitalar de S?o Jo?o, EPE, Porto, Portugal|Institut Catala de Retina, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|University Hospital of Wales, Cardiff, United Kingdom|Moorfields Eye Hospital, London, United Kingdom|Manchester Royal Eye Hospital, Manchester, United Kingdom|Queen's Hospital, Romford, United Kingdom Less << |
| NCT01495715 | Leber's Hereditary Optic Neuro... More >>pathy Less << | Phase 3 | Withdrawn | - | - |
| NCT00015808 | Friedreich Ataxia | PHASE1 | COMPLETED | 2025-04-06 | National Institute of Neurolog... More >>ical Disorders and Stroke (NINDS), Bethesda, Maryland, 20892, United States Less << |
| NCT02887443 | Drug-Drug Interaction | Phase 1 | Completed | - | France ... More >> Eurofins Optimed Gières, France, 38610 Less << |
| NCT00078481 | Friedreich Ataxia | PHASE1 | COMPLETED | 2025-04-06 | National Institute of Neurolog... More >>ical Disorders and Stroke (NINDS), Bethesda, Maryland, 20892, United States Less << |
| NCT00654784 | Duchenne Muscular Dystrophy (D... More >>MD) Less << | Phase 2 | Completed | - | Belgium ... More >> Children's Hospital, University Hospital Leuven, Belgium Less << |
| NCT02771379 | Leber's Hereditary Optic Neuro... More >>pathy (LHON) Less << | COMPLETED | 2021-04-16 | Universitaetsklinikum Graz, Gr... More >>az, 8036, Austria|Medical University of Vienna, Vienna, Austria|CHU de N?mes - H?pital Carémeau, N?mes, Gard, 30029, France|CHU Angers - H?pital H?tel Dieu, Angers, Maine Et Loire, 49033, France|Hopital Roger Salengro - CHU Lille, Lille, Nord, 59037, France|H?pital Européen Georges Pompidou, Paris, Paris Cedex 15, 75908, France|CHU Amiens - Centre Saint Victor, Amiens, Somme, 80054, France|Hopital Neurologique Pierre Wertheimer, Lyon Cedex, 69677, France|Hospices Civils de Lyon, Lyon, 69002, France|Centre Hospitalier National d'Ophtalmologie (CHNO) des Quinze-Vingts, Paris, 75012, France|Fondation Ophtalmologique Adolphe de Rothschild, Paris, 75019, France|Julius Maximilians University, Wuerzburg, Bavaria, 97070, Germany|Universitaetsklinikum Essen, Essen, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, 20246, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Friedrich-Baur-Institut, Munich, Germany|Universitaetsklinikum Muenster, Munster, Germany|Dietrich-Bonhoeffer-Klinikum Neubrandenburg, Neubrandenburg, Germany|Universitaetsklinikum Regensburg, Regensburg, Germany|Athens Ophthalmological Center, Athens, 11528, Greece|Università di Bologna-Clinica Neurologica-Dipartimento di Scienze Neurologiche, Bologna, 40123, Italy|Ospedale San Raffaele, Milano, 20132, Italy|Azienda Ospedaliera S. Camillo Forlanini, Rome, 00152, Italy|Universitair Medisch Centrum Groningen, Groningen, 9713 GZ, Netherlands|Maastricht University Medical Center, Maastricht, 6211 LK, Netherlands Less << | |
| NCT01854359 | Multiple Sclerosis|Primary Pro... More >>gressive Multiple Sclerosis Less << | PHASE1|PHASE2 | COMPLETED | 2018-10-31 | National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less << |
| NCT00537680 | Friedreich's Ataxia | Phase 3 | Completed | - | United States, California ... More >> David Geffen School of Medicine, UCLA Los Angeles, California, United States, 90095-1769 United States, Pennsylvania The Children's Hopsital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 Less << |
| NCT00654784 | - | Completed | - | - | |
| NCT00950248 | Primary Progressive Multiple S... More >>clerosis Less << | Phase 1 Phase 2 | Completed | - | United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less << |
| NCT00537680 | - | Completed | - | - | |
| NCT00229632 | Friedreich Ataxia | PHASE2 | COMPLETED | 2007-12-17 | National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less << |
| NCT00747487 | Leber's Hereditary Optic Neuro... More >>pathy Less << | Phase 2 | Completed | - | Canada, Quebec ... More >> Unité de recherche clinique Ophtalmologie- Hopital Notre-Dame Montreal, Quebec, Canada, H2L 4M1 Germany Klinikum der Universität München - Grosshadern, Neurologische Klinik und Poliklinik Munich, Germany, 81377 United Kingdom Clinical Research Facility, 4th Floor Leazes Wing, Royal Victoria Infirmary Newcastle Upon Tyne, United Kingdom, NE1 4LP Less << |
| NCT02814019 | Duchenne Muscular Dystrophy (D... More >>MD) Less << | Phase 3 | Recruiting | August 2019 | - |
| NCT00905268 | - | Completed | - | - | |
| NCT00697073 | Friedreich's Ataxia | PHASE3 | COMPLETED | 2025-05-10 | David Geffen School of Medicin... More >>e, UCLA, Los Angeles, California, 90095-1769, United States|The Children's Hopsital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States Less << |
| NCT00697073 | Friedreich's Ataxia | PHASE3 | COMPLETED | 2025-05-10 | David Geffen School of Medicin... More >>e, UCLA, Los Angeles, California, 90095-1769, United States|The Children's Hopsital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States Less << |
| NCT01027884 | Muscular Dystrophy, Duchenne ... More >> Ambulatory Care Less << | Phase 3 | Completed | - | - |
| NCT01027884 | - | Completed | - | - | |
| NCT00905268 | Friedreich's Ataxia | Phase 3 | Completed | - | Austria ... More >> Universitätsklinik Innsbruck Innsbruck, Austria, 6020 Belgium Hôpital Erasme - Université Libre de Bruxelles Bruxelles, Belgium, 1070 France Hôpital de la Salpêtrière - INSERM U679, Neurologie et Thérapeutique expérimentale Paris, France, 75651 Germany HELIOS Klinikum BerlinBuch Berlin, Germany, 13125 Neurologische Universitätsklinik und Poliklinik- Universitätsklinikum Bonn Bonn, Germany, 53105 Klinik II, Neuropädiatrie u.Muskelerkrankungen- Universitätsklinik Freiburg Freiburg, Germany, 79106 Zentrum für Neurologische Medizin Göttingen, Germany, 37073 UKE Hamburg Neuropädiatrie-Zentum für Frauen, Kinder und Jugendmedizin Hamburg, Germany, 20246 Neurologische Klinik- klinikum Grosshadern München, Germany, 81377 Neurologische Universitätsklinik und Poliklinik Tübingen, Germany, 72076 Netherlands University Medical Center Groningen Groningen, Netherlands, 9700 RB United Kingdom National Hospital for Neurology & Neurosurgery London, United Kingdom, WC1N 3BG University of Newcastle upon Tyne -Mitochondrial Research Group Newcastle, United Kingdom, NE2 4HH Less << |
| NCT00993967 | Freidreich's Ataxia | Phase 3 | Completed | - | Austria ... More >> Universitätsklinik Innsbruck Innsbruck, Austria Belgium Hôpital Erasme - Univeristé Libre de Bruxelles Bruxelles, Belgium, 1070 France Hôpital de la Salpétrière - INSERM U679, Neurologie et Thérapeutique expérimentale Paris, France, 75651 Germany HELIOS Klinikum Berlin Berlin, Germany, 13125 Neurologische Universitätsklinik und Ploklinik - Universitätsklimikum Bonn Bonn, Germany, 53105 Klinik II, Neuropädiatrie und Muskelerkrankungen - Universitätsklinik Freiburg Freiburg, Germany, 79106 Zentrum für Neurologische Medizin Göttingen, Germany, 37073 UKE Hamburg Neuropädiatrie - Zentrum für Frauen, Kinder und Jugendmedizin Hamburg, Germany, 20246 Neurologische Klinik - Klinikum Grosshadern München, Germany, 81377 Neurologische Universitätsklinik und Poliklinik Tübingen, Germany, 72076 Netherlands University medical Center Groningen Groningen, Netherlands, 9700 RB Less << |
| NCT00758225 | Duchenne Muscular Dystrophy | PHASE2 | COMPLETED | 2025-01-11 | University Hospitals Leuven, L... More >>euven, 3000, Belgium Less << |
| NCT00887562 | - | Completed | - | - | |
| NCT00993967 | - | Completed | - | - | |
| NCT03727295 | Oxidative Stress is an Importa... More >>nt Cause of Parkinson's Disease Less << | Phase 4 | Not yet recruiting | May 30, 2021 | - |
| NCT01303406 | Friedreich's Ataxia | Phase 3 | Completed | - | Austria ... More >> Innsbruck, Austria Germany Bonn, Germany München, Germany Tübingen, Germany Netherlands Groningen, Netherlands United Kingdom The National Hospital, University College London London, United Kingdom, WC 1N 3BG Less << |
| NCT03433807 | Duchenne Muscular Dystrophy | NO_LONGER_AVAILABLE | - | Phoenix Children's Hospital, P... More >>hoenix, Arizona, 85016, United States|Yale New Haven Hospital, New Haven, Connecticut, 06510, United States|Lurie Children's Hospital of Chicago, Chicago, Illinois, 60611, United States|University of Iowa, Iowa City, Iowa, 52242, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Kennedy Krieger, Baltimore, Maryland, 21287, United States|Columbia University Pediatric Neuromuscular Center, New York, New York, 10032, United States|Carolina's Healthcare System, Charlotte, North Carolina, 28207, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|University of Virginia Children's Hospital, Charlottesville, Virginia, 22904, United States|St. Luke's Rehabilitation Institute, Spokane, Washington, 99202, United States Less << | |
| NCT00887562 | MELAS Syndrome | Phase 2 | Completed | - | United States, New York ... More >> Columbia University Medical Center New York, New York, United States, 10032 Less << |
| NCT03603288 | Duchenne Muscular Dystrophy | Phase 3 | Recruiting | January 2022 | United States, Minnesota ... More >> Gillette Children's Specialty Healthcare Recruiting Saint Paul, Minnesota, United States, 55101 Contact: Randel Richardson, MD Belgium University Hospital Leuven Recruiting Leuven, Belgium, 3000 Contact: Gunnar Buyse, MD Principal Investigator: Gunnar Buyse, MD CHR Citadelle Recruiting Liège, Belgium, 4000 Principal Investigator: Laurent Servais, MD Italy Fondazione IRCCS Eugenio Medea Recruiting Bosisio Parini, Italy, 23842 Contact: Maria Grazia Nadia D'Angelo, MD Principal Investigator: Maria Grazia Nadia D'Angelo, MD Switzerland Center for neuromuscular disorders, Universitäts-Kinderspital beider Basel (UKBB) Recruiting Basel, Switzerland, 4301 Principal Investigator: Andrea Klein, MD United Kingdom Robert Jones and Agnes Hunt Orthopaedic Hospital Recruiting Oswestry, United Kingdom, SY10 7AG Contact: Tracey Willis, MD Principal Investigator: Tracey Willis, MD Less << |
| NCT01303406 | - | Completed | - | - |
Tags: Idebenone | Mitochondrial Metabolism | Apoptosis | Antioxidant | Oxidative |SHSY-5Y | neurotoxicity | Alzheimer's | Huntington's | arachidonic acid | coenzyme Q10 | dopaminergic neuroblastoma | coenzyme Q10 analog | 58186-27-9
Precautionary Statements-General | |
| Code | Phrase |
| P101 | If medical advice is needed,have product container or label at hand. |
| P102 | Keep out of reach of children. |
| P103 | Read label before use |
Prevention | |
| Code | Phrase |
| P201 | Obtain special instructions before use. |
| P202 | Do not handle until all safety precautions have been read and understood. |
| P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
| P211 | Do not spray on an open flame or other ignition source. |
| P220 | Keep/Store away from clothing/combustible materials. |
| P221 | Take any precaution to avoid mixing with combustibles |
| P222 | Do not allow contact with air. |
| P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
| P230 | Keep wetted |
| P231 | Handle under inert gas. |
| P232 | Protect from moisture. |
| P233 | Keep container tightly closed. |
| P234 | Keep only in original container. |
| P235 | Keep cool |
| P240 | Ground/bond container and receiving equipment. |
| P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
| P242 | Use only non-sparking tools. |
| P243 | Take precautionary measures against static discharge. |
| P244 | Keep reduction valves free from grease and oil. |
| P250 | Do not subject to grinding/shock/friction. |
| P251 | Pressurized container: Do not pierce or burn, even after use. |
| P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
| P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
| P262 | Do not get in eyes, on skin, or on clothing. |
| P263 | Avoid contact during pregnancy/while nursing. |
| P264 | Wash hands thoroughly after handling. |
| P265 | Wash skin thouroughly after handling. |
| P270 | Do not eat, drink or smoke when using this product. |
| P271 | Use only outdoors or in a well-ventilated area. |
| P272 | Contaminated work clothing should not be allowed out of the workplace. |
| P273 | Avoid release to the environment. |
| P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
| P281 | Use personal protective equipment as required. |
| P282 | Wear cold insulating gloves/face shield/eye protection. |
| P283 | Wear fire/flame resistant/retardant clothing. |
| P284 | Wear respiratory protection. |
| P285 | In case of inadequate ventilation wear respiratory protection. |
| P231 + P232 | Handle under inert gas. Protect from moisture. |
| P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
| Code | Phrase |
| P301 | IF SWALLOWED: |
| P304 | IF INHALED: |
| P305 | IF IN EYES: |
| P306 | IF ON CLOTHING: |
| P307 | IF exposed: |
| P308 | IF exposed or concerned: |
| P309 | IF exposed or if you feel unwell: |
| P310 | Immediately call a POISON CENTER or doctor/physician. |
| P311 | Call a POISON CENTER or doctor/physician. |
| P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
| P313 | Get medical advice/attention. |
| P314 | Get medical advice/attention if you feel unwell. |
| P315 | Get immediate medical advice/attention. |
| P320 | |
| P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
| P321 | |
| P322 | |
| P330 | Rinse mouth. |
| P331 | Do NOT induce vomiting. |
| P332 | IF SKIN irritation occurs: |
| P333 | If skin irritation or rash occurs: |
| P334 | Immerse in cool water/wrap n wet bandages. |
| P335 | Brush off loose particles from skin. |
| P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
| P337 | If eye irritation persists: |
| P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
| P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P342 | If experiencing respiratory symptoms: |
| P350 | Gently wash with plenty of soap and water. |
| P351 | Rinse cautiously with water for several minutes. |
| P352 | Wash with plenty of soap and water. |
| P353 | Rinse skin with water/shower. |
| P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
| P361 | Remove/Take off immediately all contaminated clothing. |
| P362 | Take off contaminated clothing and wash before reuse. |
| P363 | Wash contaminated clothing before reuse. |
| P370 | In case of fire: |
| P371 | In case of major fire and large quantities: |
| P372 | Explosion risk in case of fire. |
| P373 | DO NOT fight fire when fire reaches explosives. |
| P374 | Fight fire with normal precautions from a reasonable distance. |
| P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
| P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
| P378 | |
| P380 | Evacuate area. |
| P381 | Eliminate all ignition sources if safe to do so. |
| P390 | Absorb spillage to prevent material damage. |
| P391 | Collect spillage. Hazardous to the aquatic environment |
| P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
| P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
| P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
| P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
| P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
| P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
| P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
| P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
| P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
| P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
| P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
| P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
| P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
| P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
| P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
| P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
| P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
| P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
| P370 + P376 | In case of fire: Stop leak if safe to Do so. |
| P370 + P378 | In case of fire: |
| P370 + P380 | In case of fire: Evacuate area. |
| P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
| P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
| Code | Phrase |
| P401 | |
| P402 | Store in a dry place. |
| P403 | Store in a well-ventilated place. |
| P404 | Store in a closed container. |
| P405 | Store locked up. |
| P406 | Store in corrosive resistant/ container with a resistant inner liner. |
| P407 | Maintain air gap between stacks/pallets. |
| P410 | Protect from sunlight. |
| P411 | |
| P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
| P413 | |
| P420 | Store away from other materials. |
| P422 | |
| P402 + P404 | Store in a dry place. Store in a closed container. |
| P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
| P403 + P235 | Store in a well-ventilated place. Keep cool. |
| P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
| P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
| P411 + P235 | Keep cool. |
Disposal | |
| Code | Phrase |
| P501 | Dispose of contents/container to ... |
| P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
| Code | Phrase |
| H200 | Unstable explosive |
| H201 | Explosive; mass explosion hazard |
| H202 | Explosive; severe projection hazard |
| H203 | Explosive; fire, blast or projection hazard |
| H204 | Fire or projection hazard |
| H205 | May mass explode in fire |
| H220 | Extremely flammable gas |
| H221 | Flammable gas |
| H222 | Extremely flammable aerosol |
| H223 | Flammable aerosol |
| H224 | Extremely flammable liquid and vapour |
| H225 | Highly flammable liquid and vapour |
| H226 | Flammable liquid and vapour |
| H227 | Combustible liquid |
| H228 | Flammable solid |
| H229 | Pressurized container: may burst if heated |
| H230 | May react explosively even in the absence of air |
| H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
| H240 | Heating may cause an explosion |
| H241 | Heating may cause a fire or explosion |
| H242 | Heating may cause a fire |
| H250 | Catches fire spontaneously if exposed to air |
| H251 | Self-heating; may catch fire |
| H252 | Self-heating in large quantities; may catch fire |
| H260 | In contact with water releases flammable gases which may ignite spontaneously |
| H261 | In contact with water releases flammable gas |
| H270 | May cause or intensify fire; oxidizer |
| H271 | May cause fire or explosion; strong oxidizer |
| H272 | May intensify fire; oxidizer |
| H280 | Contains gas under pressure; may explode if heated |
| H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
| H290 | May be corrosive to metals |
Health hazards | |
| Code | Phrase |
| H300 | Fatal if swallowed |
| H301 | Toxic if swallowed |
| H302 | Harmful if swallowed |
| H303 | May be harmful if swallowed |
| H304 | May be fatal if swallowed and enters airways |
| H305 | May be harmful if swallowed and enters airways |
| H310 | Fatal in contact with skin |
| H311 | Toxic in contact with skin |
| H312 | Harmful in contact with skin |
| H313 | May be harmful in contact with skin |
| H314 | Causes severe skin burns and eye damage |
| H315 | Causes skin irritation |
| H316 | Causes mild skin irritation |
| H317 | May cause an allergic skin reaction |
| H318 | Causes serious eye damage |
| H319 | Causes serious eye irritation |
| H320 | Causes eye irritation |
| H330 | Fatal if inhaled |
| H331 | Toxic if inhaled |
| H332 | Harmful if inhaled |
| H333 | May be harmful if inhaled |
| H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
| H335 | May cause respiratory irritation |
| H336 | May cause drowsiness or dizziness |
| H340 | May cause genetic defects |
| H341 | Suspected of causing genetic defects |
| H350 | May cause cancer |
| H351 | Suspected of causing cancer |
| H360 | May damage fertility or the unborn child |
| H361 | Suspected of damaging fertility or the unborn child |
| H361d | Suspected of damaging the unborn child |
| H362 | May cause harm to breast-fed children |
| H370 | Causes damage to organs |
| H371 | May cause damage to organs |
| H372 | Causes damage to organs through prolonged or repeated exposure |
| H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
| Code | Phrase |
| H400 | Very toxic to aquatic life |
| H401 | Toxic to aquatic life |
| H402 | Harmful to aquatic life |
| H410 | Very toxic to aquatic life with long-lasting effects |
| H411 | Toxic to aquatic life with long-lasting effects |
| H412 | Harmful to aquatic life with long-lasting effects |
| H413 | May cause long-lasting harmful effects to aquatic life |
| H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL


